References
- Akram, M., Iqbal, M., Daniyal, M. et al. Awareness and current knowledge of breast cancer. Biol Res. 50:1-23, 2017 https://doi.org/10.1186/s40659-016-0106-3
- 국가암정보센터 [cited 2019 Nov 14] Available from:URL: https://www.cancer.go.kr/lay1/program/S1T211C217/cancer/view.do?cancer_seq=4757&menu_seq=4762
- 윤미란, 류지영, 송병주, 채병주, 유태경. 호르몬 수용체 약양성 유방암과 삼중음 성 유방암의 치료 예후. 한국유방암학회. 7:1-8, 2019 https://doi.org/10.4048/jkbcs.2004.7.1.1
- Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do WeGo From Here? Oncology (Williston Park). 30:148-155, 2016
- 한가진, 이아람, 성신, 김성수. 진행성 유방암에 대한 한양방 병용 치료 치험 1례. 대한한방내과학회지. 9:268-276, 2018
- 한가진, 이아람, 정준석, 성신, 김성수. 유방암에 대한 한양방 병용 치료 증례 보고 1례. 대한한방내과학회지. 38:820-827, 2017 https://doi.org/10.22246/jikm.2017.38.5.820
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1). Eur J Cancer 45:228-247, 2009 https://doi.org/10.1016/j.ejca.2008.10.026
- Karcioglu O, Topacoglu H, Dikme O (2018) A systematic review of the pain scales in adults: Which to use? Am J Emerg Med. 36:707-714, 2018 https://doi.org/10.1016/j.ajem.2018.01.008
- National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.4.0, 2010. [cited 2019 Nov 10] Available from:URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html)
- Guo YH, Kuruganti R, Gao Y. Recent Advances in Ginsenosides as Potential Therapeutics Against Breast Cancer. Curr Top Med Chem. 1:1-5, 2019. https://doi.org/10.2174/1568026013395560
- 전국한의과대학 본초학교수 공편저. 본초학. p. 531, 서울, 영림사, 1994
- 중약대사전편찬위원회. 완역중약대사전. 권7. p. 3473-3479, 서울, 정담, 1997
- Nakhjavani, M., Hardingham, J.E., Palethorpe, H.M., Tomita, Y., Smith, E., Price, T.J., et al. Ginsenoside rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines. 6:17-37, 2019 https://doi.org/10.3390/medicines6010017
- Lee, H., Lee, S., Jeong, D. & Kim, S. J. Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells. J. Ginseng Res. 42:455-462, 2018 https://doi.org/10.1016/j.jgr.2017.05.003
- Zhu J, Zhang H, Zhu Z, et al. Effects and mechanism of flavonoids from Astragalus complanatus on breast cancer growth. Naunyn Schmiedebergs Arch Pharmacol. 388:965-972, 2015 https://doi.org/10.1007/s00210-015-1127-0
- Li W, Song K, Wang S, et al. Anti-tumor potential of astragalus polysaccharides on breast cancer cell line mediated by macrophage activation. Mater Sci Eng C Mater Biol Appl. 98:685-695, 2019 https://doi.org/10.1016/j.msec.2019.01.025
- Zhou R, Chen H, Chen J, Chen X, Wen Y, Xu L. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 18:83, 2018 https://doi.org/10.1186/s12906-018-2148-2
- Madden, R., Kosari, S., Peterson, G.M., Bagheri, N., Thomas, J. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review. Int. J. Clin. Pharmacol. Ther. 56:72-80, 2018 https://doi.org/10.5414/cp203123
- Martin Huertas, R., Fernandez Abad, M., Corral de la Fuente, E., et al. Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response. Breast J. 2:5-9, 2019
- Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER 2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18:732-742, 2017 https://doi.org/10.1016/S1470-2045(17)30312-1